Uterine Fibroids Treatment Drugs Market Stimulated by Rising...

Uterine Fibroids Treatment Drugs Market Stimulated by Rising Uterine Fibroids Prevalence

Posted 2024-08-12 12:46:44

522

Uterine fibroids, also known as leiomyomas or myomas, are benign smooth muscle tumors that develop in the uterus. The precise cause of uterine fibroids is unknown, however genetic factors and estrogen are considered contributors to their development. Uterine fibroids are very common occurring in up to 80% of women by the age of 50. Symptoms include heavy or painful periods, pelvic pressure or pain, bloating, bladder pressure and fertility issues. The conventional treatment options include medication such as hormonal therapies like combined oral contraceptives and progestins to shrink fibroids. Other treatment options include surgical procedures like hysterectomy and myomectomy.

The uterine fibroids treatment drugs market is estimated to be valued at USD 1.87 Bn in 2024 and is expected to reach USD 3.19 Bn by 2031, growing at a compound annual growth rate (CAGR) of 7.9% from 2024 to 2031.

Key Takeaways

Key players operating in the Uterine Fibroids Treatment Drugs are Myovant Sciences, Pfizer, Bayer AG, AstraZeneca, AbbVie Inc., Abbott Healthcare Pvt. Ltd., Sun Pharmaceuticals Industries Ltd., Zydus Cadila Healthcare Ltd., Gedeon Richter plc, Ipsen Pharma, Teva Pharmaceutical Industries Ltd., TerSera Therapeutics, Takeda Pharmaceutical Company Limited, Ferring Pharmaceuticals, Amring Pharmaceuticals Inc., and Biocon Biologics. The increasing prevalence of uterine fibroids, growing gynecological issues among women, and rising awareness about treatment options are the key opportunities in the market. Novel drugs in the pipeline like Myovant's Relugolix and Abbvie's Elagolix are expected to drive growth in the uterine fibroids treatment drugs market.

Market Drivers

The key driver fueling the Uterine Fibroids Treatment Drugs Market Demand is the rising demand for minimally invasive treatment options. Medication provides a non-surgical treatment alternative to hysterectomy and myomectomy for symptomatic relief. Drugs can shrink fibroids and reduce heavy bleeding significantly to alleviate symptoms. This is expected to increase the uptake of drugs over surgery. Another factor is the growing awareness about uterine fibroids among women encouraging them to seek treatment promptly.

Get More Insights on- Uterine Fibroids Treatment Drugs Market